avelumab in patients with relapsed or recurrent ovarian cancer
Published 9 years ago • 574 plays • Length 2:27Download video MP4
Download video MP3
Similar videos
-
1:24
dr. jeffrey infante on the positive results of using avelumab in patients with ovarian cancer
-
6:34
bevacizumab’s value in recurrent ovarian cancer
-
6:40
keynote-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer
-
4:30
ovarian cancer: therapeutic management at recurrence
-
1:00
rationalizing use of pembrolizumab/bevacizumab in recurrent ovarian cancer
-
5:33
recurrent advanced ovarian cancer: case impressions
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
2:55
audio described: clinical trial tests nivolumab for patients with rare brain and spine cancers
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
3:03
durvalumab and oleclumab in patients with relapsed ovarian cancer
-
5:31
considerations for managing recurrent ovarian cancer
-
4:29
optimizing therapy in recurrent ovarian cancer
-
3:49
role of avelumab versus chemotherapy for untreated epithelial ovarian cancer
-
5:06
monitoring and managing patients with ovarian cancer
-
4:39
recurrent ovarian cancer: third-line therapy and beyond
-
2:18
parp inhibition in recurrent ovarian cancer
-
1:21
rucaparib may improve pfs in patients with ovarian cancer
-
0:57
dr. infante on avelumab's potential in ovarian cancer
-
5:17
outlook for patients with high-risk ovarian cancer